Network pharmacological analysis predicted the components and mechanisms of ARSHs against RA, screening 15 key components (e.g., dihydrochelerythrine, magnoflorine, etc.)and 24 core targets (e.g., SRC, STAT3, MAPK3, etc.). This evidence concerns the gene MAPK3 and rheumatoid arthritis.